Oliva C - Search Results

1

Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.

Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, Rosso R, Conte PF. Chiara S, et al. Among authors: oliva c. Eur J Cancer. 1995;31A(3):296-301. doi: 10.1016/0959-8049(94)00487-p. Eur J Cancer. 1995. PMID: 7786592 Clinical Trial.

2

Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.

Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R. Repetto L, et al. Among authors: oliva c. Anticancer Res. 1991 Jul-Aug;11(4):1641-3. Anticancer Res. 1991. PMID: 1746921

3

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience.

Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone M, Sertoli MR, Parodi GC, Ragni N, Foglia G, Odicino F, et al. Chiara S, et al. Among authors: oliva c. Eur J Cancer. 1991;27(10):1211-5. doi: 10.1016/0277-5379(91)90083-p. Eur J Cancer. 1991. PMID: 1835588

4

Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens.

Repetto L, Chiara S, Pace M, Guido T, Bruzzone M, Oliva C, Murolo C, Conte PF, Rosso R. Repetto L, et al. Among authors: oliva c. Tumori. 1990 Jun 30;76(3):274-7. doi: 10.1177/030089169007600313. Tumori. 1990. PMID: 2195729

5

CA-125 monitoring in the management of ovarian cancer.

Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T, Merlini L, Parodi S, Bentivoglio G, Ventrella W, et al. Bruzzone M, et al. Among authors: oliva c. Anticancer Res. 1990 Sep-Oct;10(5A):1353-9. Anticancer Res. 1990. PMID: 2241112

6

The impact of received dose intensity on the outcome of advanced ovarian cancer.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al. Repetto L, et al. Among authors: oliva c. Eur J Cancer. 1993;29A(2):181-4. doi: 10.1016/0959-8049(93)90169-g. Eur J Cancer. 1993. PMID: 8422279 Clinical Trial.

7

Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.

Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C. Rosso R, et al. Among authors: oliva c. Anticancer Res. 1991 Mar-Apr;11(2):937-9. Anticancer Res. 1991. PMID: 1829602 Clinical Trial.

8

Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).

Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R. Campora E, et al. Among authors: oliva c. Oncology. 1991;48(5):403-5. doi: 10.1159/000226969. Oncology. 1991. PMID: 1836058

9

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.

Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R. Campora E, et al. Among authors: oliva c. Breast Cancer Res Treat. 1991 Oct;19(2):129-32. doi: 10.1007/BF01980943. Breast Cancer Res Treat. 1991. PMID: 1836746 Clinical Trial.

10

Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors.

Mammoliti S, Bruzzone M, Chiara S, Vidali A, Miglio L, Fontana V, Oliva C, Compora E, Giuntini P, Centonze M, et al. Mammoliti S, et al. Among authors: oliva c. Anticancer Res. 1992 Sep-Oct;12(5):1415-8. Anticancer Res. 1992. PMID: 1444199

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters